(Press Release) SOLX®, Inc., a privately held company dedicated to developing innovative surgical technologies that treat glaucoma and preserve vision, has announced that Kevin McMahon has joined the company as president and chief executive officer. He replaces Doug Adams, SOLX’s founder and past-president and CEO.
A veteran medical device executive, McMahon brings more than 25 years of experience to the role. Most recently, he served as president and general manager of RaySafe inc., which, under his direction, was successfully acquired by Fluke Biomedical.
In his tenure, McMahon has directed several successful product launches that resulted in the acquisitions of several paradigm shifting medical technologies in the fields of Ophthalmology, Breast Cancer and Radiation Oncology.
“We are delighted to welcome Kevin to SOLX,” says Eric Bednarski, partner at MVM Life Science Partners and member of the company’s Board of Directors. “Kevin is an exceptional leader with a proven record of success in bringing innovative new products to market. I am confident that his strong commercial and operational experience will serve SOLX well as the company moves through the regulatory process to commercialization.”
“Doug is a pioneer in the field of glaucoma. We thank Doug for his entrepreneurial efforts in advancing SOLX and, as Founder, his continuing support of the company,” adds Bednarski.
“The company has a strong history of advancing the development of the SOLX Gold Shunt, a novel, minimally invasive device that has the potential to improve the surgical treatment of glaucoma, especially for those patients with difficult to treat refractory glaucoma,” says McMahon.
“This is an exciting time for the company as we finalize our regulatory process and move toward commercialization. There is a great, unmet need for additional treatment options for patients who struggle with glaucoma, which affects 65 million patients worldwide. I am proud to be affiliated with a company that has continued to dedicate itself to developing better solutions for glaucoma surgeons and their patients.”
For more information, visit www.solx.com.